The drug inhibits HER2 dimer formation with other HER family members, such as HER3 and HER1. Genentech is currently studying a combination of both HER2 inhibitors in breast cancer. “With this ...

Background: Variable rates of HER2 protein overexpression and gene amplification have been reported in advanced ovarian cancers (AOC). Trastuzumab, tested only as a single agent, has been shown to ...